Provided by Tiger Fintech (Singapore) Pte. Ltd.

CureVac B.V.

4.46
+0.02000.45%
Volume:437.52K
Turnover:1.94M
Market Cap:1.00B
PE:5.15
High:4.51
Open:4.42
Low:4.31
Close:4.44
Loading ...

CureVac NV Reports Increased Sales and Net Income in 2024, EPS Rises Significantly

Reuters
·
23 May

CureVac NV reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
22 May

Stock Track | CureVac Stock Plummets 5.14% Ahead of Expected Q1 Earnings Report

Stock Track
·
21 May

Stock Track | CureVac Soars 5.17% as Strong Cash Position Outweighs Revenue Decline

Stock Track
·
20 May

Stock Track | CureVac Soars 5.17% on Strong Cash Position and Extended Runway Despite Q1 Revenue Decline

Stock Track
·
20 May

CureVac Q1 Sales $946.45K Miss $3.34M Estimate, Company Exits Quarter With Cash And Equivalents Worth $460.91M

Benzinga
·
20 May

BRIEF-Curevac Q1 Revenue Eur 900 Thousand

Reuters
·
20 May

CureVac Nv - Strong Cash and Cash Equivalents Position of EUR 438.3 Mln as of March 31, 2025

THOMSON REUTERS
·
20 May

CureVac Nv - Net Financial Result for Q1 of 2025 Amounted to EUR 3.0 Mln

THOMSON REUTERS
·
20 May

CureVac Nv - Year-on-Year Decrease in Revenues Was Primarily Driven by Lower Revenues From GSK Following Restructuring of Partnership in July 2024 From a Collaboration Into a Licence Agreement as Well as Lower Sales to CRISPR Therapeutics

THOMSON REUTERS
·
20 May

CureVac Nv - Reaffirming Expected Cash Runway Into 2028

THOMSON REUTERS
·
20 May

CureVac NV expected to post a loss of 19 cents a share - Earnings Preview

Reuters
·
19 May

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
19 May

CureVac (CVAC) Receives a Hold from Leerink Partners

TIPRANKS
·
19 May

CureVac : Deutsche Bank Raises Target Price to $3.5 From $2.5

THOMSON REUTERS
·
16 May

BRIEF-Curevac Receives Additional Positive Validity Decision From European Patent Office In Ongoing Litigation Against Biontech SE

Reuters
·
16 May

CureVac Nv - Epo Dismisses Opposition by BioNTech and Pfizer on Patent Ep 4 023 755 B1

THOMSON REUTERS
·
16 May

Eqs-News: CureVac Receives Additional Positive Validity Decision From European Patent Office in Ongoing Litigation Against BioNTech Se

THOMSON REUTERS
·
16 May

Curevac Is Maintained at Buy by UBS

Dow Jones
·
30 Apr

UBS Trims Price Target on CureVac to $12 From $13, Maintains Buy Rating

MT Newswires Live
·
30 Apr